Literature DB >> 22762545

Phospholipid vesicle-bound lysozyme to enhance permeability in human intestinal cells.

Wasu Witoonsaridsilp1, Busaba Panyarachun, Montree Jaturanpinyo, Narong Sarisuta.   

Abstract

BACKGROUND: Oral peptide and protein drug delivery still remain the area of challenges for pharmaceutical scientists due to their low stability and permeability in gastrointestinal (GI) tract. In this study phospholipid vesicle-bound lysozyme were prepared and assessed for their physicochemical properties, secondary structure, and permeation across Caco-2 cells.
RESULTS: Lysozyme was found to be substantially bound onto negatively charged vesicles via electrostatic interaction as evidenced by zeta potential measurements regardless of cholesterol content. In contrast, the size of phospholipid vesicle-bound lysozyme became larger with the increasing cholesterol content. The secondary structure of vesicle-bound lysozyme examined by FTIR was unchanged compared to that in buffer solution. The apparent permeability of vesicle-bound lysozyme across Caco-2 cells monolayer was significantly enhanced with a size dependent manner compared to that of solution.
CONCLUSION: The permeation across Caco-2 cell monolayers of phospholipid vesicle-bound lysozyme was demonstrated to be significantly enhanced with a size-dependent manner.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22762545     DOI: 10.3109/10837450.2012.700930

Source DB:  PubMed          Journal:  Pharm Dev Technol        ISSN: 1083-7450            Impact factor:   3.133


  2 in total

1.  The Effect of Particle Size on the Absorption of Cyclosporin A Nanosuspensions.

Authors:  Wenjun Sun; Jing Gao; Ranran Fan; Ting Zhang; Yang Tian; Zengming Wang; Hui Zhang; Aiping Zheng
Journal:  Int J Nanomedicine       Date:  2022-04-19

2.  The Study of Cyclosporin A Nanocrystals Uptake and Transport across an Intestinal Epithelial Cell Model.

Authors:  Wenjun Sun; Yang Tian; Zengming Wang; Hui Zhang; Aiping Zheng
Journal:  Polymers (Basel)       Date:  2022-05-12       Impact factor: 4.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.